The new mRNA vaccines target the KP. 2 variant because most recent covid cases are caused by that strain or closely related ones. The Novavax vaccine targets the JN. 1 variant that recent variants ...

The story of mRNA vaccines dates back to the early 1990s, when Hungarian-born researcher Katalin Kariko of the University of Pennsylvania started testing mRNA technology as a form of gene therapy.

While the new, approved COVID-19 vaccines are the first mRNA vaccines to be licensed by the FDA, the technology has been in use for cancer research since at least 2011.

A researcher of Stermirna Therapeutics Co., Ltd. shows the experiment to develop an mRNA vaccine targeting the novel coronavirus in east China's Shanghai. Ding Ting / Xinhua via Getty Editor's ...

They then create a single mRNA that triggers the body to make these proteins – just as COVID-19 vaccines trigger production of the spike protein that sits on the surface of the virus.

It’s true that mRNA vaccines would probably have come to market eventually, but they were on what Dieffenbach calls “a leisurely stroll.” Covid “pressure-tested” them—advancing their ...

Indeed, an mRNA vaccine has never been mass-produced and licensed to treat an infectious disease. The mRNA vaccines to treat the novel coronavirus would be the first.

With this backdrop, we believe that COVID-19 survivors should only get one dose of mRNA vaccine (made by Pfizer and Moderna) which would speed the rate of immunization by allowing others to get ...

When the final Phase 3 data came out last November showing the mRNA vaccines made by Pfizer/BioNTech and Moderna were more than 90% effective, Dr. Anthony Fauci had no words. He texted smiley face ...